MFAP3L predicts tumor microenvironment status, molecular subtypes and clinical benefit in patients with bladder cancer Authors: Guoou Xie, Tiezheng Qi, Yiyan Yao, Dongcai Feng, Weimin Zhou Published: 2024 ABSTRACT AbstractBladder cancer (BLCA), ranking as the tenth most prevalent malignancy globally, imposes a substantial public health and socio-economic challenge. Despite ongoing efforts by urologists to identify novel molecular subtypes and treatment paradigms, the intrinsic heterogeneity of BLCA continues to obstruct the efficacy of current diagnostic and therapeutic evaluations, leaving a gap in the comprehensive management of BLCA. This necessitates an in-depth investigation into the BLCA tumor microenvironment (TME) to identify pivotal molecules like MFAP3L. Our research concentrated on MFAP3L, commencing with a pan-cancer analysis of its immune profile. We discovered that MFAP3L exhibits a significant negative correlation with numerous immune components and markers in BLCA, a trend not observed in other cancer types. Within the TCGA-BLCA cohort, patients were classified into High-MFAP3L and Low-MFAP3L groups according to their MFAP3L transcript levels. Our exploration into the BLCA TME delved into immune infiltration, molecular subtype patterns, and treatment preferences within these MFAP3L groups. High MFAP3L expression was linked to favorable prognoses, luminal subtypes, and low immune infiltration, inversely associated with various immune molecules and characteristics. Additionally, high MFAP3L expressors exhibited diminished immune checkpoint levels, suggesting enhanced immunotherapy tolerance and sensitivity to oncogenic pathway targeting. Conversely, low MFAP3L expression correlated with poor outcomes, basal subtypes, increased immune infiltration, and heightened gene mutation rates, alongside sensitivity to radiotherapy, EGFR-targeted treatments, and immunotherapy. Hence, MFAP3L emerges as a critical yet underexplored gene in BLCA, offering insights into immune status within the TME and aiding in molecular subtyping and therapeutic decision-making.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-024-77971-w.Keywords: Bladder cancer, Tumor microenvironment, Microfibril-associated protein 3-like, Molecular subtypeSubject terms: Bladder cancer, Immunosuppression Introduction Bladder cancer (BLCA) is a prevalent global malignancy, presenting significant health and economic challenges due to its high morbidity and mortality within the urinary system1. Despite advancements in medical technology, including promising treatments such as neoadjuvant chemotherapy and immunotherapy, clinical outcomes for the majority of patients remain unsatisfactory. The tumor microenvironment (TME) is a complex ecosystem of tumor cells, adjacent cells, stroma, and blood vessels, which is critical for the occurrence of tumor immune responses2. Its significant heterogeneity leads to varied clinical outcomes, with mutations and abnormal expression of multiple molecules playing a crucial role in this process3,4. In response, our research utilizes genomics to investigate potential key genes within the BLCA TME, aiming to uncover novel molecular functions. Our research aims to develop innovative molecular stratification tools and quantification systems, thereby enhancing precision medicine approaches for BLCA treatment. Microfibril-associated protein 3-like (MFAP3L) has emerged as a gene of interest due to its potential involvement in the BLCA TME. MFAP3L, a member of the microfibril-associated glycoprotein (MAGP) family, has been highlighted in recent studies for its significant role in oncogenesis and tumor progression5. Initially identified and cloned from a human testis cDNA library, MFAP3L exhibits strong expression in the testis and prostate, with minimal expression in the ovary. Located on chromosome 4q32.3, the MFAP3L gene spans 15 kb and encodes a transcript of 1345 bp, which translates into a 409 amino acid single-pass membrane protein. Notably, phosphorylation and glycosylation sites have been identified on the extracellular domain of MFAP3L, suggesting its involvement in cell-to-cell interactions, possibly through the EGFR signaling pathway6. In addition, other members of the MAGP family have also been linked to various cancers. MAGP-1 has been implicated in extracellular matrix remodeling in colorectal cancer (CRC)7. MFAP2 is linked to a poor prognosis in hepatocellular carcinoma (HCC)8, and MFAP5 (MAGP2) is recognized as a promising biomarker for ovarian cancer9. MFAP3L, in particular, is associated with CRC progression and has been validated as a predictor for liver metastasis in CRC cases6. These findings underscore the potential importance of MAGP family proteins, including MFAP3L, in cancer biology and highlight their promise as therapeutic targets. However, the role of MFAP3L in BLCA remains to be elucidated. This study aims to investigate the association between MFAP3L expression in BLCA, its molecular subtypes, and clinical outcomes. The goal is to utilize MFAP3L expression patterns to inform precise treatment strategies. Methods and materials Data preparation and preprocessing Xiangya cohort The Xiangya BLCA cohort comprises 57 BLCA samples and 13 normal bladder tissues collected from Xiangya Hospital, providing a comprehensive RNA sequencing profile detailed in prior research10. This dataset has been made publicly available in the Gene Expression Omnibus (GEO) database under the accession number GSE188715. Public database Transcriptome data for two cohorts (GSE 32548 and 13507) were obtained in the GEO database using the “GEOquery” R package. Data of IMvigor210 trial, a clinical study employing atezolizumab to block PD-L1 in BLCA patients, were downloaded from http://research-pub.gene.com/IMvigor210CoreBiologies/. We extracted and compiled a comprehensive RNA-seq dataset along with clinical annotations. Finally, the integrated pan-cancer expression data, comprising over 30 cancer types, were obtained from the UCSC Xena Database (https://xenabrowser.net/datapages/). Evaluation of BLCA molecular subtypes Utilizing the “BLCAsubtyping” and “ConsensusMIBC” R package, seven molecular subtype systems can be used to classify patients with BLCA, including Baylor11, TCGA12, MDA13, UNC14, Lund15, CIT16, and Consensus17. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the efficacy of MFAP3L in predicting BLCA molecular subtype systems. Identification of immune-related differentially expressed RNAs (DERs) BLCA patients were stratified according to the median expression level of MFAP3L. The “ESTIMATE” R package was employed to calculate the immune and stromal scores of the TCGA-BLCA cohort. By integrating these scores with MFAP3L expression levels, we identified immune-related and stromal-related DERs by “Limma” R package. Additionally, we investigated the potential correlation between MFAP3L and the mutation frequency of genes associated with neoadjuvant chemotherapy (NAC). Enrichment pathways analysis DEGs in bulk RNA-seq data were filtered by “Limma” R package, with a screening threshold for |log (fold change)|> 1.5 and the adjusted p-value < 0.05. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted on identified DEGs by “ClusterProfiler” R package18–20. The “Seurat” R package and FindMarker algorithms were used to identify genes specifically expressed in the scRNA-seq. The common DERs were identified by “VennDiagram” R package. Evaluation of Immunological Identity of TME in BLCA The relationship between MFAP3L and 122 immunomodulators, essential immune cells, and the anti-tumor immune cycle was investigated, as well as its association with several validated targets. Information on the 122 immunomodulators was obtained from the work of Charoentong et al21.. Two independent algorithms (TIMER and MCP-COUNTER) were employed to calculate the infiltration levels of tumor-infiltrating immune cells (TIICs). Effector genes of TIICs are collected to assess functional status. The seven-step cancer immune cycle was evaluated through the Tracking tumor immunophenotype (TIP) website (http://biocc.hrbmu.edu.cn/TIP/). To investigate the potential of MFAP3L in the field of immunotherapy, 18 genes for calculating T-cell inflammation score (TIS)22and 22 genes associated with immune checkpoint blockade (ICB) markers23 were collected for further analysis. Statistical analysis Data analysis was performed within R (Version 4.2.2), considering p-values < 0.05 as significant. Gaussian-distributed data were analyzed with t-tests, non-Gaussian with Mann-Whitney U-tests, and categorical variables with chi-square tests. All tests were two-sided and aligned with biological and medical standards. Results Comprehensive analysis revealing negative correlation of MFAP3L with immune in BLCA To offer insights into the influence of MFAP3L on immune, we conducted a comprehensive analysis to investigate its correlation with immunomodulators, key immune cell populations, and the anti-tumor immune cycle. In pan-cancer analysis, MFAP3L expression showed a positive correlation with most immunomodulators (Fig. 1A) across different cancer types, including prostate cancer (TCGA-PRAD), colorectal cancer (TCGA-COAD), and uterine carcinosarcoma (TCGA-UCS). However, in BLCA (TCGA-BLCA), this correlation was negative. This distinct pattern suggests that MFAP3L warrants further investigation in BLCA. Correlations between MFAP3L with immunological characteristics in pan-cancers. (A) Correlation between MFAP3L and 122 immunomodulators, including chemokines, receptors, MHC, immunostimulants, and immunosuppressants. (B) Correlation between MFAP3L and tumor-associated immune cells. The color indicates the correlation coefficient. The asterisks indicate a statistically significant p-value calculated using Spearman’s correlation analysis. *represented P < 0.05, **represented P < 0.01, *** represented P < 0.001, and NS signified P > 0.05. (C–F) Correlation between MFAP3L and four immune checkpoints, namely PD-L1, CTLA-4, PD-1, and LAG-3. The dots represented cancer types. The Y-axis represented the Pearson correlation, while the X-axis represented -log 10 P. We also observed a significant negative correlation between MFAP3L and immune cells (Fig. 1B), particularly macrophages and CD8 + T cells. Additionally, the expression of MFAP3L in BLCA showed a strong negative correlation with four commonly studied inhibitory immune checkpoints (Fig. 1C), namely programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3). Overall, our findings suggest that MFAP3L plays a unique role in BLCA and may influence anti-tumor immunity. MFAP3L shapes a non-inflamed TME in BLCA In the TCGA-BLCA cohort, we further explored the immunological role of MFAP3L. Our analysis revealed that patients with low MFAP3L expression exhibited higher immune cell infiltration and more robust anti-tumor immune cycle activity (Fig. 2A). For a molecular target to be considered for potential immunotherapy, it must influence the infiltration of TIICs24. Two independent algorithms were employed to calculate the infiltration levels of TIICs. Consistent with our previous findings, low MFAP3L expression was associated with significant increases in key immune cells, including CD8 + T cells, macrophages, and neutrophils. This indicates enhanced immune infiltration and recruitment, regardless of the algorithm used (Supplementary Fig. 1A-B). MFAP3L correlated with the tumor immune microenvironment in BLCA. (A) Heat-map showed differences in the level of immune cell infiltration and the various steps of the antitumor immune cycle in the high and low MFAP3L groups in BLCA. (B) Heat-map showed differential expression of effector genes of five mentioned TIICs between high and low MFAP3L group in BLCA. (C) Correlation between MFAP3L with TIS and the corresponding TIS related effector genes. (D) Correlation between MFAP3L and 22 inhibitory immune checkpoint genes. (E) Differential expression of key immune molecules between high and low MFAP3L group. Data were presented as median and IQR. (F) Differential expression of MFAP3L in different immune phenotypes. Data were presented as median and IQR. The asterisks indicate a statistically significant p value calculated using the Mann-Whitney U test or Spearman’s correlation analyses. *represented P < 0.05, **represented P < 0.01, *** represented P < 0.001, and NS signified P > 0.05. Meanwhile, TIICs in the low MFAP3L group exhibited elevated levels of effector genes, particularly T-cell signatures associated with ICB treatment response (Fig. 2B). Overall, the activity of the cancer immune cycle, including tumor antigen release, immune system recognition, immune cell recruitment, and tumor killing, reflects the comprehensive interaction of the chemokine system and other immune modulators. We found that the low MFAP3L group demonstrated increased tumor antigen exposure, anti-tumor immune activation, recruitment of essential anti-tumor immune cells, and effective tumor recognition and destruction (Supplementary Fig. 1C). Notably, a negative correlation between MFAP3L with cancer immune cycles, and TIICs was validated in other public cohorts (IMvigor210, GSE32548, and GSE13507) (Supplementary Figs. 2A-B, 3A and E). An exception was observed in the NK cells of the IMvigor210 cohort, which exhibited higher infiltration levels in the high MFAP3L group. Next, we calculated the TIS and found that TIS was higher in the low MFAP3L group (Supplementary Fig. 1D). Similarly, a statistically significant negative correlation was observed between MFAP3L expression and almost all TIS genes and various immune checkpoint inhibitors (ICIs) (Fig. 2C-D). Furthermore, key immune molecules previously identified as being associated with the non-inflamed TME, such as Siglec1525, S100A526, and BCAT227 showed significant associations with MFAP3L in the BLCA (Fig. 2E). Our findings underscore the significance of MFAP3L in forecasting the immune status of TME. In the IMvigor210 cohort, we validated this conclusion (Fig. 2F). The predictive value of MFAP3L for molecular subtypes and treatment response Within the TCGA-BLCA cohort, individuals with elevated MFAP3L levels demonstrated improved prognosis (p= 0.015, Fig. 3A), often correlating with the luminal subtype. This subtype is characterized by heightened luminal and urothelial differentiation, as well as enrichment in the Ta pathway (Fig. 3B). Accordingly, reduced MFAP3L expression was linked to the basal subtype, characterized by a preference for basal differentiation and pathways associated with immunity, such as interferon signaling, along with stromal pathways like epithelial-mesenchymal transition (EMT). Moreover, it is generally accepted that the basal subtype (low MFAP3L group) has higher infiltration of cytotoxic lymphocytes and NK cells17. This is consistent with our previous finding. MFAP3L predicts the molecular subtype and response to several therapies in BLCA. (A) Kaplan-Meier survival curves for OS of patients from TCGA cohort. (B) Heat-map showed correlations between MFAP3L and molecular subtypes with seven different subtyping systems. (C) ROC analysis on the prediction accuracy of MFAP3L for molecular subtypes. The accuracy was equal to the area under the ROC curves. (D, E) Mutational profiles of neoadjuvant chemotherapy-related genes in low and high MFAP3L group. Genes ranked by their frequency of mutation and categorized by variant type in patients. (F) Heat-map showed correlation between MFAP3L and the enrichment scores of therapeutic signatures. (G) Difference in mRNA expression of hyperprogression associated genes between the low and high MFAP3L group. Data were presented as median and IQR. The asterisks indicate a statistically significant p value calculated using the Mann-Whitney U test or t-test. *represented P < 0.05, **represented P < 0.01, *** represented P < 0.001, and NS signified P > 0.05. (H) The difference in copy number variation patterns of hyperprogression associated genes between the low and high MFAP3L group. The p value was calculated with the Fisher t-test. Molecular subtypes and genetic alterations are known to influence the immune status of TME and the response to treatment, including ICB, NAC, and targeted therapies. To better classify patients, we investigated the association between MFAP3L and molecular typing as well as gene mutations. Our analysis revealed that MFAP3L exhibited high accuracy in predicting bladder cancer (BLCA) molecular subtypes, with the area under the ROC curves (AUC) ranging from 0.84 to 0.96 (Fig. 3C). In other three external validation cohorts, low MFAP3L expression was predominantly associated with the basal subtype, whereas high MFAP3L expression was correlated and the luminal subtype (Supplementarys Figs. 2C, 3B and F). These findings highlight the robust predictive value of MFAP3L for molecular subtyping, as evidenced by an AUC score exceeding 0.80 in the IMvigor210 cohort (Supplementary Fig. 2D). Patients with basal subtype tumors more likely to respond to NAC28. Analysis of NAC-related gene mutations revealed a lower mutation rate in the high-MFAP3L group (54%) compared to the low-MFAP3L group (basal subtype, 68.84%). This suggested that patients with lower MFAP3L expression may derive greater benefit from NAC treatment (Fig. 3D-E). Considering the importance of ICB and NAC therapy, we focused on pathways associated with treatment response. Enrichment score analysis indicated that the low MFAP3L group was more sensitive to EGFR-targeted therapy and radiotherapy. The high MFAP3L group showed higher enrichment scores for immunosuppressive oncogenic pathways, commonly associated with a non-inflamed TME (Fig. 3F). These results were confirmed in three external cohorts (Supplementary Figs. 2E, 3C and G). Due to the existence of ICB-associated hyperprogression, we conducted an analysis of the expression levels of relevant genes. We found that genes negatively associated with hyperprogression exhibited high expression levels in the low MFAP3L group, whereas genes positively associated with hyperprogression showed low expression levels in the same group (Fig. 3G-H). In summary, we confirmed the capacity of MFAP3L to predict molecular subtypes. Patients with low MFAP3L expression are more likely to respond to EGFR-targeted therapy, radiotherapy, ICB and NAC therapy. Furthermore, we found that low MFAP3L expression is associated with higher infiltration of cytotoxic lymphocytes and NK cells, enhanced immune infiltration, and increased tumor antigen exposure. Genes negatively associated with ICB-related hyperprogression exhibited higher expression levels in the low MFAP3L group, suggesting a favorable immunological environment for these patients. Validation in the Xiangya cohort In the Xiangya cohort, the low MFAP3L group exhibited higher levels of key immune cells, such as macrophages, NK cells, and neutrophils. In contrast, the high MFAP3L group showed reduced immune cell presence (Fig. 4A). Additionally, MFAP3L expression was inversely associated with most immune checkpoints, including PD-1 and PD-L1, but positively correlated with VTCN1 and CEACAM1 (Fig. 4B). Furthermore, a negative correlation was observed between MFAP3L expression and increased tumor antigen release, as well as the recruitment of tumor-fighting immune cells, highlighting MFAP3L’s pivotal role in cancer immunity (Fig. 4C). The analysis also revealed that high MFAP3L expression corresponded to luminal subtypes and pathways associated with urothelial differentiation, whereas low MFAP3L expression was aligned with basal subtypes and their related pathways (Fig. 4D). Additionally, MFAP3L proved to be a robust predictor for BLCA molecular subtypes, with AUC values ranging from 0.74 to 0.94 (Fig. 4E). Our findings highlight the potential of MFAP3L in the field of personalized treatment. Patients with high MFAP3L expression may benefit from therapies targeting oncogenic pathways, while those with low MFAP3L expression may benefit from EGFR-targeted and radiation therapies (Fig. 4F). The successful replication of these results in the Xiangya cohort confirms the significant influence of MFAP3L in BLCA. Validation of the MFAP3L prediction for immunological characteristics, molecular subtypes, and the response to therapies in the Xiangya cohort. (A) Correlations between MFAP3L and the infiltration levels of tumor-associated immune cells. Data were presented as median and IQR. (B) Correlations between MFAP3L and 19 immune checkpoints. (C) Correlations between MFAP3L and the process of the anti-cancer immunity cycle. (D) Heat-map showed correlations between MFAP3L and seven molecular subtype systems. (E) ROC curves showed the accuracy of MFAP3L in predicting classical molecular subtypes. (F) Heat-map showed correlation between MFAP3L and the enrichment scores of therapeutic. The asterisks indicate a statistically significant p value calculated using the Mann-Whitney U test. *represented P < 0.05, ** represented P < 0.01, *** represented P < 0.001, and NS signified P > 0.05. Discussion MFAP3L is a key MAGP family protein whose role has been explored primarily in CRC. Previous studies have suggested that this molecule is significantly associated with CRC progression and metastasis6. Our study delves into MFAP3L’s role in BLCA, focusing on its unique role in BLCA and its potential in anti-tumor immunity. Our findings reveal that MFAP3L expression significantly influences BLCA treatment outcomes, serving as a crucial factor in tailoring therapeutic strategies, including immunotherapy, targeted therapy, and conventional treatments like radiotherapy. By elucidating MFAP3L’s impact on the BLCA TME and its relationship with treatment efficacy, we enable the development of personalized treatment plans. These plans aim to improve clinical outcomes by leveraging the tumor’s molecular profile, thereby advancing precision medicine in BLCA. Our investigation confirmed that MFAP3L inversely correlates with several critical immunomodulators essential for immune cell recruitment within the BLCA TME. Additionally, we observed a negative correlation between MFAP3L levels and the infiltration of CD8 T cells, CD4 T cells, and dendritic cells, indicating that higher MFAP3L expression is associated with non-inflamed tumor phenotypes and potentially reduced sensitivity to ICIs. This inverse relationship also extends to key immune checkpoints, including PD-L1, PD-1, CTLA-4, and LAG-3, suggesting that MFAP3L expression may significantly influence the effectiveness of immunotherapy. In multiple cohorts, a link between MFAP3L expression and the efficacy of different therapies was established. Low MFAP3L expression correlates with the basal subtype and an improved response to ICB and neoadjuvant therapies. In contrast, high MFAP3L expression is indicative of the luminal subtype, which is more amenable to targeted treatments, such as those inhibiting β-catenin, PPAR-γ, FGFR3 pathways, and anti-angiogenic therapies. Our findings revealed that the group with low MFAP3L expression showed elevated levels of immune cell infiltration, but exhibited a shorter overall survival. Notably, most patients in the low MFAP3L group were classified into the basal molecular subtype, which is typically associated with higher clinical grade and poorer prognosis17. These results further reinforce the significance of molecular subtype systems in forecasting tumor progression and treatment response. Furthermore, it offers a potential explanation for the shorter survival observed in the low MFAP3L group. The studies conducted by Kuo-Hao Ho et al. and Han Zeng et al. have identified a subgroup of cancer patients with a poor prognosis and high levels of immune cell infiltration29,30. These findings indicate that a poor prognosis and high immune cell infiltration are not necessarily mutually exclusive. The reclassification of BLCA patients based on molecular heterogeneity introduces a novel approach to enhancing therapeutic outcomes. MFAP3L plays a role in the induction of a non-inflamed TME, which positions it as a potential immunotherapy target for BLCA treatment. Moreover, our findings suggest that MFAP3L has the potential to serve as a predictive marker for molecular subtypes and to inform the development of personalized anti-tumor therapies. Despite the insightful findings, our study has certain limitations. Primarily, it relies heavily on bioinformatics analysis, lacking in vitro experimental validation to substantiate the observed associations. Additionally, the sample size of our Xiangya cohort, comprising just over 50 samples, may not provide the robustness needed for large-scale validation. Furthermore, a comprehensive understanding of MFAP3L’s role in the BLCA TME would benefit from multi-omic approaches, including proteomics and metabolomics, to offer a more detailed molecular characterization. These gaps underscore the need for further research to validate and expand upon our findings. Future research should focus on experimental validation and a more detailed molecular characterization to strengthen and expand upon our findings. Conclusion Our study identifies MFAP3L as a crucial factor in the BLCA TME. MFAP3L can predict the prognosis and molecular subtypes in BLCA patients. Additionally, it can guide the selection of appropriate treatment strategies for patients. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We sincerely thank all the participants in the study. Author contributions G.X.: conception, wrote the main manuscript text , and Funding acquisition. T.Q. and Y.Y.: collection and assembly of data, prepared all figures and supplementary figures. D.F. and W.Z.: writing-Reviewing and editing, supervision and validation. All authors reviewed the manuscript. Funding This work was supported by Scientific Research Project of Hunan Provincial Health Commission (Grant No.D202304058683). Data availability Pan-cancer expression data: https://xenabrowser.net/datapages/. Data of IMvigor210 cohort: http://research-pub.gene.com/IMvigor210CoreBiologies/. Data of Xiangya cohort: The data was collected at Xiangya Hospital and uploaded to the GEO database, number GSE188715. Data of GSE 32548 and 13507: GEO database. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Dongcai Feng, Email: 2466295137@qq.com. Weimin Zhou, Email: zhouwm0223@163.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Pan-cancer expression data: https://xenabrowser.net/datapages/. Data of IMvigor210 cohort: http://research-pub.gene.com/IMvigor210CoreBiologies/. Data of Xiangya cohort: The data was collected at Xiangya Hospital and uploaded to the GEO database, number GSE188715. Data of GSE 32548 and 13507: GEO database.